Biotechnology China’s National Medical Products Administration (NMPA) has granted approval for BeiGene’s tislelizumab, in combination with fluoropyrimidine and platinum chemotherapy, for the first-line treatment of patients with local- advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma with high PD-L1 expression 27 February 2023